Hikma acquires portfolio of Takeda brands for MENA region

Mubasher: Hikma Pharmaceuticals has agreed with Takeda Pharmaceuticals International AG to develop a portfolio of products in the MENA region.

The multinational pharmaceutical group plans to acquire the rights to 17 brands licensed to Hikma for select territories across the region, according to a press release.

The portfolio includes growing branded products used for cardiovascular, diabetes, gastroenterology, and pain management.

Hikma will commercialise all 17 brands, with further plans to move the manufacture of these products in-house. This will ensure the continuity of supply of these important medicines, which are widely used by patients across the region.

Subject to customary legal and regulatory closing conditions, the acquisition will result in enhanced efficiency and cost-saving opportunities, which will boost the profitability of the branded business.

Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA, said: “By bringing these products in-house, we will not only ensure an uninterrupted supply of products to our customers but will also have better control of our supply chain, which will result in cost saving opportunities over the medium term.”

“We are confident this acquisition will strengthen our Branded business and reinforce our commitment to provide high-quality medicines to patients in MENA,” Darwazah added.

Mubasher Contribution Time: 22-Dec-2024 08:48 (GMT)
Mubasher Last Update Time: 22-Dec-2024 08:48 (GMT)